The Kirsten rat sarcoma viral G12C (KRASG12C) protein is one of the most common
mutations in non-small-cell lung cancer (NSCLC). KRASG12C inhibitors are promising for …

Objectives:< p> Identify the etiology of squamous cell lung cancer.</p>< p> Review the
appropriate history, physical, and evaluation of squamous cell lung cancer.</p>< p> Outline …

Background Lung adenocarcinoma (LUAD) is the one of the most common subtypes in lung
cancer. Although various targeted therapies have been used in the clinical practice, the 5 …

The continuing evolution of treatment options in thoracic oncology requires the pathologist to
regularly update diagnostic algorithms for management of tumor samples. It is essential to …

Hepatocellular carcinoma (HCC) is one of the most common malignancies and the third
leading cause of cancer-related deaths globally. Hepatic arterial infusion chemotherapy …

PURPOSE The addition of checkpoint inhibitors to first-line treatment has prolonged survival
of patients with non–small-cell lung cancer (NSCLC), but prognosis remains poor, with new …

Simple Summary Early-stage disease non-small cell lung cancer has better outcomes than
advanced disease, but 5-year survival rates can drop to approximately 50% in cases of …

Background The introduction of immunotherapy in the treatment of non-small cell lung
cancer (NSCLC) has resulted in a radical change in patients' treatment responses and …

Simple Summary The use of liquid biopsy for tumor genomic profiling to identify genomic
biomarkers for targeted therapies has revolutionized the clinical practice in oncology …

Though immunotherapy has to some extent improved the prognosis of patients with
advanced non‐small cell lung cancer (NSCLC), only a few patients benefit. Furthermore …